Refine by
Cancerous Target Equipment & Supplies
131 equipment items found
by:Da Zen Theranostics, Inc. based inSilicon Valley, CALIFORNIA (USA)
Circumventing drug toxicity and drug resistance is key to effective anticancer therapy. Da Zen’s products and technologies deliver targeted anticancer drugs, such as simvastatin and cisplatin conjugated to a cancer targeting dye-carrier, exclusively to cancer cells, with the drugs confined to the cancer ...
Premium
Manufactured by:Vobis LLC based inEaston, PENNSYLVANIA (USA)
We have developed proprietary lipid based nano technologies that have potential benefits in different therapeutic areas including targeted cancer therapy, DNA Vaccination and liver diseases. Here are the some of the highlights related to our LNP and liposomal experience including type of liposomes and techniques. ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: EG12014/EGI014 Trastuzumab Biosimilar. Indication: Cancer. Target: HER2. Status: ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: EG1206A Pertuzumab Biosimilar. Indication: Cancer. Target: HER2. Status: Phase ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: New Formulation. Indication: Cancer. Target: HER2. Status: ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: EG12021 Bevacizumab Biosimilar. Indication: Cancer. Target: VEGF. Status: ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: TSY0110 (EG12043) Antibody-Drug Conjugate. Indication: Cancer. Target: HER2. Status: ...
by:Astraveus based inParis, FRANCE
They exhibit abilities to survive solid tumor microenvironment, to trigger inflammation and to absorb and digest debris or infected cells. CAR-Macrophages (CAR-M) are artificially directed against a cancerous target by a chimeric antigen receptor. CAR-M are still in their clinical infancy, however specific abilities of macrophages make them a promising approach ...
Manufactured by:Cancer Targeted Technology based inWoodinville, WASHINGTON (USA)
CTT1057 is an innovative 18F-labeled PET agent for prostate cancer that can be imaged within 2 hours of administration. CTT1057 will specifically and sensitively detect cancer that has escaped from the prostate as well as distant metastatic disease including bone metastases with greater precision and resolution than current standard of care. With uncertainty in how to interpret PSA test results, ...
Manufactured by:Cancer Targeted Technology based inWoodinville, WASHINGTON (USA)
CTT’s lead therapeutic product, CTT1403, is a PSMA-targeted 177Lu-labeled agent for prostate cancer that can has superior binding characteristics, long circulation half-life, enhanced tumor uptake and unparalleled anti-tumor efficacy. CTT1403 will specifically deliver the radionuclide, 177Lu, minimizing toxic side effects and more effectively treating ...
by:Genmab A/S based inCopenhagen V, DENMARK
Amivantamab is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform. The two antibody libraries used to produce amivantamab were both ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and ...
by:CDR-Life based inSchlieren, SWITZERLAND
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly ...
by:PharmAI GmbH based inDresden, GERMANY
The technology behind PharmAI’s DiscoveryEngine allows for an unprecedented level of detail in the representation of drug-target complexes. Besides geometric comparison of binding sites based on local alignments, non-covalent interactions were included as they significantly improve the prediction of binding site similarities. Over many years, PharmAI refined and improved ...
Manufactured by:ALL Chemistry Inc. based inMarlton, NEW JERSEY (USA)
TJ191 is a selective anti-cancer agent, targeting low TβRIII-expressing malignant T-cell leukemia/lymphoma ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells. While HIRE molecules provide cancer cells specific targeting, and exert bi-modal proliferative inhibition, any cancer ...
Manufactured by:Khloris Biosciences, Inc. based inMountain View, CALIFORNIA (USA)
iPSC vaccination presents a differentiated approach to cancer treatment, targeting a panoply of antigens, leveraging the patient's immune system for optimized antigen presentation, and engaging both cellular and humoral ...
Manufactured by:VECT-HORUS based inMARSEILLE, FRANCE
Vect-Horus has developed its “VECTrans®” breakthrough technology platform with the objective of making the ‘undruggable’ druggable by overcoming challenges of the BBB, and more generally biological barriers. VECTrans® is based on the specific design and optimization of ‘molecular vectors’ that, once conjugated to a payload, enable its delivery to target ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
Our first multi-targeted Treatment System is comprised of VOR33-CLL1 multiplex-edited eHSC therapy and VCAR33-CLL1 multi-specific CAR-T therapy. Knocking out CD33 and CLL-1 through gene editing offers a promising new approach to treating patients with AML using our novel eHSC platform. Our research demonstrates that multiplex genome editing of allogeneic hematopoietic stem cells ...
Manufactured by:Reglagene Holding, Inc. based inTucson, ARIZONA (USA)
RGN3118 is a potent, orally administered, blood-brain barrier penetrant therapy that has been optimized for the treatment of high-grade gliomas, such as glioblastoma as well as brain metastases from breast, lung, and melanoma cancers. ...